KuppingerCole's Advisory stands out due to our regular communication with vendors and key clients, providing us with in-depth insight into the issues and knowledge required to address real-world challenges.
Optimize your decision-making process with the most comprehensive and up-to-date market data available.
Compare solution offerings and follow predefined best practices or adapt them to the individual requirements of your company.
Configure your individual requirements to discover the ideal solution for your business.
Meet our team of analysts and advisors who are highly skilled and experienced professionals dedicated to helping you make informed decisions and achieve your goals.
Meet our business team committed to helping you achieve success. We understand that running a business can be challenging, but with the right team in your corner, anything is possible.
Bob holds a deep understanding and knowledge of the healthcare supply chain, including compliance issues, current standards and technologies. His ability to harness his expertise and innovate around the complexities of regulatory compliance, cross-industry operations and emerging technology, has made him a trusted industry and regulator partner.
Bob often serves as an advisor to State Boards of Pharmacy, the US FDA, USAID and other federal agencies. He has advised international governing organizations such as the Pakistani FDA, EU Commission and Health Canada. He was chosen to administer the US FDA Drug Supply Chain Security Act Pilot Program, lead the industry in developing the Center’s Digital Trust Framework for the Drug Supply Chain Security Act. Celeste launched the Center for Supply Chain Studies in 2015 to continue his practice of utilizing strategic simulations to address the challenges and demands of the supply chain. HIs expertise extends across many industries, including Pharmaceutical, Consumer Goods, Fresh Foods, Aerospace, Automotive, Specialty Chemicals and others.
Prior to founding the Center, Bob was Sr. Director at GS1 US where he worked with industry on standards-based, item-level traceability leading to the publication of the first Drug Supply Chain Security Act implementation guideline.
